A study led by Harvard Medical School, explored the reason that causes the rise of aortic aneurysms, thus offering vital ...

Indian firms have secured rights to produce Lenacapavir, a twice-yearly HIV injection, making treatment easier and affordable. This new drug promises better adherence and wider access, especially in ...

Indian firms have secured rights to produce Lenacapavir, a twice-yearly HIV injection, making treatment easier and affordable ...

The FDA's approval of lenacapavir, a highly effective HIV prevention drug, sparks debate in India due to its high cost of ₹24 ...

WASHINGTON — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global ...

Like other PrEP drugs, if enough of the medication is present when a person is exposed to HIV, it can prevent the virus from ...

The National Institutes of Health office responsible for issuing federal guidelines related to treatment of HIV and AIDS ...

These four BofA Securities Growth 10 stocks come with reliable dividends and are are timely ideas for growth and income ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...

While Gilead Sciences’ HIV prevention drug lenacapavir got approved by the US FDA, its made-in-India generic versions may be ...